Published in Clin Exp Immunol on February 01, 1979
Immune complexes in serum and in cerebrospinal fluid in African trypanosomiasis. Correlation with polyclonal B cell activation and with intracerebral immunoglobulin synthesis. J Clin Invest (1981) 1.55
Murine V lambda x and V lambda x-containing antibodies bind human myelin basic protein. J Clin Invest (1996) 0.86
Cellular and humoral immunity in subacute sclerosing panencephalitis. Infect Immun (1981) 0.85
Intracerebral synthesis of antibodies to measles and distemper viruses in patients with subacute sclerosing panencephalitis and multiple sclerosis. Clin Exp Immunol (1980) 0.84
Measles-virus antibody and antigen in subacute sclerosing panencephalitis. Lancet (1967) 5.44
Isolation of measles virus from cell cultures of brain from a patient with subacute sclerosing panencephalitis. N Engl J Med (1969) 4.76
Diagnosis and classification of multiple sclerosis. Br Med Bull (1977) 4.68
Measles antibodies in multiple sclerosis. Proc Soc Exp Biol Med (1962) 3.14
Immunoglobulins in multiple sclerosis and infections of the nervous system. Arch Neurol (1971) 2.51
Oligoclonal IgG antibody response in the central nervous system to different measles virus antigens in subacute sclerosing panencephalitis. Proc Natl Acad Sci U S A (1973) 2.10
Formation and absorption of cerebrospinal fluid in man. Brain (1968) 2.07
Oligoclonal measles virus-specific IgG antibodies isolated from cerebrospinal fluids, brain extracts, and sera from patients with subacute sclerosing panencephalitis and multiple sclerosis. Scand J Immunol (1976) 1.66
The immunogenesis of the multiple sclerosis plaque. Brain Res (1971) 1.62
Measles and other virus-specific immunoglobulins in multiple sclerosis. Br Med J (1973) 1.57
Comparison of antibodies against different viruses in cerebrospinal fluid and serum samples from patients with multiple sclerosis. Infect Immun (1974) 1.48
On cerebrospinal fluid immunoglobulin-G (IgG) quotients in multiple sclerosis and other diseases. A review and a new formula to estimate the amount of IgG synthesized per day by the central nervous system. J Neurol Sci (1970) 1.35
Antibodies to oligodendroglia in patients with multiple sclerosis. N Engl J Med (1977) 1.20
Electrophoretic morphology of gamma globulins in cerebrospinal fluid of multiple sclerosis and other diseases of the nervous system. Neurology (1970) 1.19
Production of antibody by the central nervous system in subacute sclerosing panencephalitis. Neurology (1968) 1.10
Additional data on measles virus antibody and antigen in subacute sclerosing panencephalitis. Neurology (1968) 1.08
Intracisternal virus-like particles in brain of a multiple sclerosis patient. J Neurol Sci (1976) 1.03
Recovery of Paramyxovirus from the jejunum of patients with multiple sclerosis. Lancet (1977) 1.02
Search for anti-encephalitogen antibody in human demyelinative diseases. Neurology (1968) 0.98
Binding of 125 I myelin basic protein by serum and cerebrospinal fluid. Clin Exp Immunol (1972) 0.95
Subacute sclerosing panencephalitis: brain immunoglobulin-G, measles antibody and albumin. Neurology (1968) 0.89
Measles virus antibodies in serum and cerebrospinal fluid in patients with multiple sclerosis and other neurological disorders, with special reference to measles antibody synthesis within the central nervous system. J Neurol Sci (1975) 0.89
Absence of measles-virus antigen in jejunum of multiple-sclerosis patients. Lancet (1977) 0.85
Jejunal immunopathology in amyotrophic lateral sclerosis and multiple sclerosis. Identification of viral antigens by immunofluorescence. Lancet (1977) 0.81
Spinal fluid differences in experimental allergic encephalomyelitis and multiple sclerosis. Science (1978) 0.81
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J Exp Med (1970) 4.92
Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J Exp Med (1970) 4.29
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology (1973) 3.41
Conglutinin and immunoconglutinins. Adv Immunol (1967) 3.16
Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry (1976) 2.89
Deficiency of C3 inactivator in man. J Immunol (1971) 2.86
Inactivator of the third component of complement as an inhibitor in the properdin pathway. Proc Natl Acad Sci U S A (1972) 2.84
Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest (1974) 2.81
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
The immunological specificity of a macrophage inhibition factor. Immunology (1970) 2.66
Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol (1972) 2.60
Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol (2000) 2.59
The physiological breakdown of the third component of human complement. Mol Immunol (1980) 2.50
British Society for Allergy and Clinical Immunology guidelines for the management of egg allergy. Clin Exp Allergy (2010) 2.44
Reaction mechanism of the alternative pathway of complement fixation. Lancet (1973) 2.38
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol (1994) 2.36
Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). Eur J Immunol (1984) 2.20
The purification of specific antibody as F(ab')2 by the pepsin digestion of antigen-antibody precipitates, and its application to immunoglobulin and complement antigens. Immunochemistry (1971) 2.16
Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA (1988) 2.13
The incidence, aetiology and management of anaphylaxis presenting to an accident and emergency department. QJM (1996) 2.07
Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med (1982) 2.04
Hereditary angio-oedema: a review with particular reference to pathogenesis and treatment. Clin Allergy (1971) 2.00
A sedimentation pattern technique for measuring conglutination: its application to demonstrating immunoconglutinins to C'4. Immunology (1966) 1.95
The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol (1996) 1.94
The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol (1975) 1.93
Role of C3b in the breakdown of C3 in hypocomplementaemic mesangiocapillary glomerulonephritis. Lancet (1973) 1.93
The preparation and properties of alexinated intermediates that react with conglutinin. I. Guinea-pig complement. Immunology (1966) 1.92
Allergy to insect stings: a review. J R Soc Med (1985) 1.91
Three rat monoclonal antibodies to human C3. Immunology (1980) 1.91
The preparation and properties of alexinated intermediates that react with conglutinin. II. Equine, rabbit and human complement. Immunology (1966) 1.88
Interpretation of tests for nut allergy in one thousand patients, in relation to allergy or tolerance. Clin Exp Allergy (2003) 1.87
Successful oral tolerance induction in severe peanut allergy. Allergy (2009) 1.86
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest (1991) 1.79
Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clin Exp Immunol (1985) 1.76
BSACI guidelines for the management of drug allergy. Clin Exp Allergy (2009) 1.74
Conglutinin binding polyethylene glycol precipitation assay for immune complexes. Clin Exp Immunol (1979) 1.71
Anaphylaxis caused by neostigmine. Anaesthesia (2000) 1.70
The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol (1991) 1.68
Food allergy in childhood. Arch Dis Child (2003) 1.67
Hereditary angio-oedema treated with E-aminocaproic acid. Br J Dermatol (1969) 1.64
Identification of Ss protein as murine C4. Nature (1975) 1.63
Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res (1993) 1.63
Deficiency of factor B of the complement system in sickle cell anaemia. Br Med J (1976) 1.61
The in vivo behaviour of complement-coated red cells: studies in C6-deficient, C3-depleted and normal rabbits. Clin Exp Immunol (1970) 1.60
The behaviour of complement and platelets in lethal endotoxin shock in rabbits. Int Arch Allergy Appl Immunol (1973) 1.60
Detection of intrapulmonary hemorrhage with carbon monoxide uptake. Application in goodpasture's syndrome. N Engl J Med (1976) 1.60
The relationship of desoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies. Clin Exp Immunol (1968) 1.58
Detection of IgA antibodies by the red cell linked antigen-antiglobulin reaction: antibodies in the sera of infants to milk proteins. Int Arch Allergy Appl Immunol (1965) 1.56
Complement genetics in relation to HLA. Br Med Bull (1978) 1.55
The frequency and clinical significance of specific IgE to both wasp (Vespula) and honey-bee (Apis) venoms in the same patient. Clin Exp Allergy (1998) 1.55
Initiation of complement activation. Springer Semin Immunopathol (1984) 1.54
A second case of human C3b inhibitor (KAF) deficiency. Clin Exp Immunol (1977) 1.50
The immunogloblin nature of nephritic factor (NeF). Clin Exp Immunol (1978) 1.47
Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines. Clin Exp Allergy (2011) 1.46
The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b). J Exp Med (1975) 1.43
Deficiency of the second component of complement associated with anaphylactoid purpura and presence of mycoplasma in the serum. Clin Exp Immunol (1973) 1.42
Complement-mediated lysis of liposomes produced by the reactive lysis procedure. Immunology (1970) 1.42
Studies on the terminal stages of complement lysis. Immunology (1973) 1.40
Venom allergy. BMJ (1998) 1.38
Combined genetic deficiency of C6 and C7 in man. Clin Exp Immunol (1978) 1.38
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol (1995) 1.37
Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells. Eur J Immunol (1978) 1.37
An iatrogenic autoantibody: immunological responses to 'pituitary snuff' in patients with diabetes insipidus. Clin Exp Immunol (1966) 1.35
Immunoconglutinins in human saliva--a group of unusual IgA antibodies. Immunology (1970) 1.35
Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement (1987) 1.35
Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure (1994) 1.34
An improved purification procedure for the third component of complement and beta 1H globulin from human serum. Mol Immunol (1979) 1.34
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest (1996) 1.33
Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g. J Immunol (1984) 1.32
Immunity deficiency in pathogenesis of glomerulonephritis. Lancet (1974) 1.31
Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology (2001) 1.31
Systemic absorption of inhaled epinephrine. Clin Pharmacol Ther (1986) 1.30
Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J Gen Virol (1990) 1.29
Activation of the alternative complement pathway by lymphoblastoid cell lines derived from patients with Burkitt's lymphoma and infectious mononucleosis. Cell Immunol (1976) 1.28
Raising antibodies by coupling peptides to PPD and immunizing BCG-sensitized animals. Ciba Found Symp (1986) 1.28
Allotypes of complement components in man. Transplant Rev (1976) 1.27
Inherited structural variation and linkage relationships of C7. J Immunogenet (1978) 1.26
Purification of cobra venom factor from phospholipase A contaminant. Immunology (1976) 1.25
Measles virus receptor on human T lymphocytes. Nature (1975) 1.24
The fractionation of antigen-dependent macrophage migration inhibition and macrophage activation factors from lymph draining a tuberculin reaction. Scand J Immunol (1974) 1.24
Inherited deficiencies of the terminal components of human complement. Immunodefic Rev (1992) 1.24
The paraproteins in systemic capillary leak syndrome. Clin Exp Immunol (1993) 1.22
Lymphocyte cooperation. Proc R Soc Lond B Biol Sci (1971) 1.21
Erythrocyte complement receptor type 1, immune complexes, and the rheumatic diseases. Arthritis Rheum (1988) 1.21
Specific IgE antibodies in the diagnosis of atopic disease. Clinical evaluation of a new in vitro test system, UniCAP, in six European allergy clinics. Allergy (1998) 1.19
The regulation of IgG subclass production in man: low serum IgG4 in inherited deficiencies of the classical pathway of C3 activation. Eur J Immunol (1988) 1.18
Restoration of specific immunological virginity. Nature (1974) 1.16
Consent and confidentiality--where are the limits? An introduction. J Med Ethics (2003) 1.15
Cellular immunity in subacute sclerosing panencephalitis. Proc R Soc Med (1974) 1.14
Lesions due to complement in lipid membranes. Nature (1971) 1.13